Restfine is a sleep-management product that contains melatonin as its active component. It is supplied as a 10 mg oral pill designed to support the regulation of the sleep-wake cycle. In Hong Kong, melatonin-containing products are regulated as health supplements, and Restfine is marketed without a prescription requirement.
Melatonin is a hormone naturally produced by the pineal gland in response to darkness. It binds to melatonin receptors MT₁ and MT₂ in the brain, signaling that it is time to prepare for sleep. By mimicking the body’s own melatonin, the supplement helps synchronize the internal circadian rhythm, reducing the time needed to fall asleep. Onset of action typically occurs within 30 minutes after ingestion, with peak plasma concentrations reached in about an hour and a duration of effect lasting 4-8 hours.
Restfine is approved for use as a short-term aid in managing occasional sleep disturbances, particularly difficulty falling asleep (sleep onset insomnia). In Hong Kong, health-supplement regulations allow melatonin products to be marketed for supporting normal sleep patterns, but they are not classified as prescription medicines for chronic insomnia. The primary patient group includes adults who experience transient sleep-related issues, such as stress-induced insomnia.
Melatonin has been studied for several off-label applications, including jet-lag mitigation, shift-work sleep disorder, and as an adjunct in certain neurological conditions. While clinical research suggests potential benefits in these areas, regulatory agencies in Hong Kong have not approved Restfine for these specific indications.
Disclaimer: Off-label use of melatonin requires medical supervision and individualized risk assessment.
Absolute contraindications
Known hypersensitivity to melatonin or any inactive ingredient in the pill.
Relative contraindications
Pregnancy or breastfeeding: caution is advised because safety data are limited.
Children and adolescents: use only under professional guidance due to variable dosing requirements.
Severe hepatic impairment: melatonin metabolism may be altered, warranting dose adjustment.
Special populations
Older adults may be more sensitive to sedative effects; start with the lowest effective dose.
Routine laboratory monitoring is not required for short-term melatonin use. Individuals using Restfine for more than several weeks should periodically evaluate sleep quality and any emerging side effects with a healthcare professional.
This article provides educational information about Restfine and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
Melatonin is commonly employed to reduce jet-lag symptoms by advancing or delaying the sleep phase, depending on the direction of travel. Use should start a few days before departure and continue for several nights after arrival, under professional guidance.
Restfine tablets typically bear the numeric code “10 MG” followed by the brand logo on one side; the opposite side may display a smooth, unmarked surface. Pill appearance can vary by manufacturer, so verification with the packaging is recommended.
Melatonin is not listed as a prohibited substance by major sporting or aviation authorities, but athletes and pilots should disclose supplement use to relevant regulatory bodies to avoid inadvertent violations.
Melatonin works by regulating the natural sleep-wake cycle, whereas zolpidem is a synthetic hypnotic that directly induces sleep through GABA-mediated inhibition. Melatonin generally has a milder side-effect profile and lower risk of dependence.
Long-term safety data for melatonin are limited; most studies report minimal adverse effects when used at typical nightly doses. However, prolonged nightly use may affect hormonal balance in sensitive individuals, warranting periodic medical review.
Concurrent use of multiple sedative agents can increase the risk of excessive drowsiness and respiratory depression. Combining Restfine with other OTC sleep aids should only be done after consulting a pharmacist or physician.
An accidental double dose may cause heightened drowsiness or mild nausea. If severe symptoms develop, seek medical attention; otherwise, monitor for increased sleepiness and avoid operating machinery.
Current evidence does not indicate a direct effect of melatonin on glucose metabolism at standard doses, but patients with diabetes should monitor their blood sugar as part of routine care.
Excess moisture can degrade the tablet coating and potentially reduce melatonin stability. Store the product in a dry place and keep the container tightly sealed to maintain potency.
The 10 mg dosage aligns with common therapeutic ranges for adult sleep regulation and simplifies dosing schedules. Lower strengths may be available in some regions, but the 10 mg unit is the standard offering for Restfine.
